169 related articles for article (PubMed ID: 17942889)
1. CUL7 is a novel antiapoptotic oncogene.
Kim SS; Shago M; Kaustov L; Boutros PC; Clendening JW; Sheng Y; Trentin GA; Barsyte-Lovejoy D; Mao DY; Kay R; Jurisica I; Arrowsmith CH; Penn LZ
Cancer Res; 2007 Oct; 67(20):9616-22. PubMed ID: 17942889
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function.
Andrews P; He YJ; Xiong Y
Oncogene; 2006 Aug; 25(33):4534-48. PubMed ID: 16547496
[TBL] [Abstract][Full Text] [Related]
3. [Construction of antisense c-myc recombinant adenovirus and its anti-tumor effects on osteosarcoma cell lines MG-63 and U2OS].
Xie XK; Yang DS; Ye ZM; Tao HM
Ai Zheng; 2005 Mar; 24(3):292-7. PubMed ID: 15757529
[TBL] [Abstract][Full Text] [Related]
4. Induction of cullin 7 by DNA damage attenuates p53 function.
Jung P; Verdoodt B; Bailey A; Yates JR; Menssen A; Hermeking H
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11388-93. PubMed ID: 17586686
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
Mizuarai S; Yamanaka K; Kotani H
Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
[TBL] [Abstract][Full Text] [Related]
6. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.
Blyth K; Vaillant F; Hanlon L; Mackay N; Bell M; Jenkins A; Neil JC; Cameron ER
Cancer Res; 2006 Feb; 66(4):2195-201. PubMed ID: 16489021
[TBL] [Abstract][Full Text] [Related]
7. The co-expression of c-myc and p53 increases and reaches a plateau early in oral oncogenesis.
Papakosta V; Vairaktaris E; Vylliotis A; Derka S; Nkenke E; Vassiliou S; Lazaris A; Mourouzis C; Rallis G; Spyridonidou S; Anagnostopoulou S; Perrea D; Donta I; Yapijakis C; Patsouris E
Anticancer Res; 2006; 26(4B):2957-62. PubMed ID: 16886620
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells.
Huang A; Ho CS; Ponzielli R; Barsyte-Lovejoy D; Bouffet E; Picard D; Hawkins CE; Penn LZ
Cancer Res; 2005 Jul; 65(13):5607-19. PubMed ID: 15994933
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice.
Wang Y; Thakur A; Sun Y; Wu J; Biliran H; Bollig A; Liao DJ
Cancer Res; 2007 Apr; 67(8):3698-707. PubMed ID: 17440082
[TBL] [Abstract][Full Text] [Related]
10. Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples.
He C; Xiong J; Xu X; Lu W; Liu L; Xiao D; Wang D
Biochem Biophys Res Commun; 2009 Oct; 388(1):35-40. PubMed ID: 19632201
[TBL] [Abstract][Full Text] [Related]
11. [Apoptosis-related gene expression and its clinical significance of human osteosarcoma].
Wu X; Chen ZR; Zhang GJ
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):678-81. PubMed ID: 15777507
[TBL] [Abstract][Full Text] [Related]
12. Functions of myc:max in the control of cell proliferation and tumorigenesis.
Hurlin PJ; Dezfouli S
Int Rev Cytol; 2004; 238():183-226. PubMed ID: 15364199
[TBL] [Abstract][Full Text] [Related]
13. Dominant oncogenes, tumor suppressors, and radiosensitivity.
Chiarugi V; Magnelli L; Cinelli M; Turchetti A; Ruggiero M
Cell Mol Biol Res; 1995; 41(3):161-6. PubMed ID: 8589756
[TBL] [Abstract][Full Text] [Related]
14. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.
Daouti S; Li WH; Qian H; Huang KS; Holmgren J; Levin W; Reik L; McGady DL; Gillespie P; Perrotta A; Bian H; Reidhaar-Olson JF; Bliss SA; Olivier AR; Sergi JA; Fry D; Danho W; Ritland S; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2008 Feb; 68(4):1162-9. PubMed ID: 18281492
[TBL] [Abstract][Full Text] [Related]
15. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.
Kakudo Y; Shibata H; Otsuka K; Kato S; Ishioka C
Cancer Res; 2005 Mar; 65(6):2108-14. PubMed ID: 15781620
[TBL] [Abstract][Full Text] [Related]
16. N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 (NLRR1) gene in neuroblastoma.
Hossain MS; Ozaki T; Wang H; Nakagawa A; Takenobu H; Ohira M; Kamijo T; Nakagawara A
Oncogene; 2008 Oct; 27(46):6075-82. PubMed ID: 18591937
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
[TBL] [Abstract][Full Text] [Related]
18. Viral and cellular oncogenes induce rapid mitochondrial translocation of p53 in primary epithelial and endothelial cells early in apoptosis.
Nemajerova A; Wolff S; Petrenko O; Moll UM
FEBS Lett; 2005 Nov; 579(27):6079-83. PubMed ID: 16226255
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes.
Sasaki R; Narisawa-Saito M; Yugawa T; Fujita M; Tashiro H; Katabuchi H; Kiyono T
Carcinogenesis; 2009 Mar; 30(3):423-31. PubMed ID: 19126650
[TBL] [Abstract][Full Text] [Related]
20. Diabetes alters expression of p53 and c-myc in different stages of oral oncogenesis.
Vairaktaris E; Kalokerinos G; Goutzanis L; Spyridonidou S; Vassiliou S; Derka S; Nkenke E; Yapijakis C; Vylliotis A; Lazaris A; Patsouris E
Anticancer Res; 2007; 27(3B):1465-73. PubMed ID: 17595763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
